India to Mali: Albendazole Export Trade Route

Importers must obtain product registration from Mali's National DRA. The application dossier should be submitted in the Common Technical Document (CTD) format. The registration fee for imported medicines is approximately $530 USD for branded generics and specialties, and $358 USD for generics. The approval process typically spans several months, contingent upon the completeness of the submitted documentation and the DRA's evaluation timeline.

A valid Good Manufacturing Practice (GMP) certificate from the manufacturing facility is mandatory. The DRA may require an inspection of the Indian manufacturing site to verify GMP compliance, especially if the facility lacks prior approval from recognized regulatory authorities. The inspection process includes a thorough review of manufacturing processes, quality control systems, and adherence to international GMP standards.

Indian exporters of Albendazole formulations must adhere to stringent GMP standards. Facilities should possess certifications from recognized authorities such as the World Health Organization (WHO) or the U.S. Food and Drug Administration (FDA). In 2025, the FDA conducted 212 inspections of Indian drug facilities, noting a decline in serious regulatory findings compared to previous years. However, instances of non-compliance have been reported; for example, in January 2026, China's National Medical Products Administration suspended the import and sale of certain medicines from Indian manufacturers due to quality compliance failures.

To ensure compliance, Indian manufacturers should maintain up-to-date GMP certifications and be prepared for potential inspections by Mali's DRA. Regular internal audits and adherence to international quality standards are crucial to avoid regulatory actions that could impede export activities.

Between 2024 and 2026, there have been notable regulatory developments affecting Indian pharmaceutical exports:

• December 2023: India's Ministry of Health and Family Welfare revised Schedule M of the Drugs Rules, aligning GMP standards more closely with WHO guidelines. This amendment mandates enhanced quality controls across manufacturing processes. Micro, Small, and Medium Enterprises (MSMEs) were granted an extension until December 31, 2025, to comply with the new standards, provided they submitted an upgradation plan by May 11, 2025.

• January 2026: China's National Medical Products Administration suspended the import, sale, and use of two Indian-manufactured medicines due to significant deficiencies in production quality and compliance. This action underscores the importance of strict adherence to GMP standards for Indian exporters.

These developments highlight the increasing global emphasis on GMP compliance. Indian manufacturers aiming to export to Mali must ensure their facilities meet both international and Mali's specific regulatory standards to facilitate smooth importation processes.

Albendazole is a critical anthelmintic used extensively in Mali to treat parasitic worm infections, which are prevalent due to the country's tropical climate and sanitation challenges. In 2024, the Malian Ministry of Health reported that approximately 30% of the population required treatment for helminth infections, underscoring significant demand for Albendazole formulations.

The pharmaceutical market in Mali has been expanding, with healthcare spending increasing by 8% annually over the past five years. This growth is driven by government initiatives aimed at achieving universal health coverage and improving access to essential medicines. Despite these efforts, domestic pharmaceutical manufacturing remains limited, necessitating substantial imports to meet the country's needs. In 2025, Mali imported $2.5 million worth of Albendazole formulations from India alone, indicating a heavy reliance on foreign suppliers to fulfill domestic demand.

Mali imposes an MFN import duty rate of 5% on pharmaceutical products classified under HS code 30049099, which includes Albendazole formulations. Notably, these pharmaceutical imports are exempt from VAT, reducing the overall cost burden on healthcare providers and patients. As of March 2026, there are no Free Trade Agreements (FTAs) between India and Mali that specifically affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on Albendazole imports from India.

India is the predominant supplier of Albendazole formulations to Mali, accounting for 100% of the $2.5 million import market in 2025. This dominance is attributed to India's cost-effective manufacturing capabilities and the established trade relationships between the two countries. Other potential suppliers, such as China and European Union manufacturers, have not significantly penetrated the Malian market for Albendazole formulations. India's competitive pricing and the absence of substantial domestic production in Mali further solidify its position as the leading supplier of these essential medications.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 24% of the world's active pharmaceutical ingredient (API) production as of 2025. This extensive manufacturing base enables the country to produce a wide range of finished dosage forms, including tablets, capsules, and syrups containing Albendazole. The cost-effectiveness of Indian pharmaceutical manufacturing is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of 2025, India boasts numerous facilities approved by the World Health Organization's Good Manufacturing Practices (WHO-GMP) and the U.S. Food and Drug Administration (FDA), ensuring high-quality production standards for Albendazole formulations.

When comparing Albendazole formulations from India, China, and the European Union (EU), several factors come into play:

• Cost: Indian manufacturers offer Albendazole formulations at competitive prices due to lower production costs and economies of scale. Chinese manufacturers also provide cost-effective options; however, concerns about quality have been raised in some instances. EU manufacturers typically offer higher-priced formulations, reflecting stringent regulatory standards and higher production costs.

• Quality Perception: Indian pharmaceutical companies have a strong reputation for producing high-quality generic medicines, with many facilities holding WHO-GMP and FDA approvals. While Chinese manufacturers have made significant strides in quality, there have been instances of substandard products, leading to cautious perception in some markets. EU manufacturers are generally perceived as producing high-quality products, adhering to strict regulatory standards.

• Regulatory Acceptance in Mali: Mali's regulatory authorities recognize and accept pharmaceuticals from WHO-GMP and FDA-approved facilities, which many Indian manufacturers possess. Chinese and EU manufacturers also export to Mali; however, the acceptance depends on individual company certifications and compliance with Mali's regulatory requirements.

• Supply Reliability: Indian manufacturers have a robust track record of reliable supply chains, supported by extensive production capacities and established logistics networks. Chinese manufacturers have faced challenges related to regulatory compliance and quality issues, potentially affecting supply reliability. EU manufacturers maintain reliable supply chains but may have longer lead times and higher costs due to stringent regulatory processes.

The India-Mali supply chain for Albendazole formulations is characterized by:

• Manufacturing Capacity: India's pharmaceutical industry has substantial capacity for producing finished dosage forms, including Albendazole tablets and capsules. Companies like Alembic Pharmaceuticals have received FDA approvals for Albendazole tablets, indicating robust production capabilities.

• Packaging and Cold Chain Capabilities: Indian manufacturers are equipped with advanced packaging facilities and, when necessary, cold chain logistics to ensure product stability and efficacy during transportation.

• Regulatory Compliance Track Record: Indian pharmaceutical companies have a strong history of adhering to international regulatory standards, with many facilities holding WHO-GMP and FDA certifications.

• Capacity Constraints or Expansion Plans: Leading Indian manufacturers continually invest in expanding their production capacities. For instance, in November 2025, Granules India announced the establishment of a new formulations manufacturing facility in Madhya Pradesh, reflecting ongoing efforts to enhance capacity and meet global demand.

For Malian buyers sourcing Albendazole formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks related to supply disruptions and ensure a consistent supply of Albendazole formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts and storage capabilities. Indian manufacturers often offer flexible MOQs, but clear communication is essential to meet both parties' requirements.

• Payment Terms: Standard payment terms in India-Mali pharmaceutical trade include letters of credit (LC) and advance payments. Establishing mutually agreeable terms will facilitate smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence by verifying potential suppliers' certifications (e.g., WHO-GMP, FDA approvals), inspecting manufacturing facilities if possible, and assessing their track record in regulatory compliance and supply reliability.

• Regulatory Compliance: Ensure that selected suppliers comply with Mali's pharmaceutical regulatory requirements, including product registration and adherence to local quality standards.

By implementing these strategies, Malian buyers can establish a reliable and cost-effective supply chain for Albendazole formulations from India.

By adhering to these guidelines, Mali companies can establish reliable partnerships with Indian Albendazole manufacturers, ensuring the importation of high-quality pharmaceutical formulations that meet both regulatory requirements and patient needs.